作　　者： (杜晓明）; (李宁）; (方佩华）;

机构地区： 天津第四中心医院内分泌科，300140

出　　处： 《中华内分泌代谢杂志》 2017年第8期662-667,共6页

摘　　要： 女目的观察抗甲状腺药物（ATDs）治疗Graves病过程中，甲状腺刺激性抗体（thyroid stimulating antibody, TSAb）及甲状腺刺激阻断性抗体（thyroid stimulating blocking antibody, TSBAb）的变化，以及联合左甲状腺素（LT4）对TSAb及TSBAb的影响。方法运用纯化的重组Trxfus.TSHRn、Trxfus.TSHRc蛋白为抗原，使用ELISA技术检测患者血清甲状腺受体抗体（TRAb）-N（以TSAb为主）、TRAb-C（以TSBAb为主）水平。回顾分析117例TRAb-N（＋）的Graves甲状腺功能亢进症（甲亢）患者ATDs治疗36个月中TRAb-N和TRAb-C的变化。ATDs治疗过程中，根据是否联合LT4分为两组，观察TRAb-N、TRAb-C的变化。结果（1）117例TRAb-N（＋）Graves甲亢患者TRAb-N变化趋势不同。Ⅰ 组：10例患者持续TRAb-N（＋）且TRAb-C（－），甲亢缓解率0%。Ⅱ组：17例患者TRAb-N变化复杂、反复波动，甲亢12例复发、5例缓解，甲亢缓解率29.4%。Ⅲ组：89例患者TRAb-N逐渐转阴，甲状腺功能15例复发、74例缓解，甲亢缓解率83.1%。卡方检验3组间有统计学差异（P〈0.01）。（2）ATDs治疗中，根据是否联合LT4分为2组，A组联合治疗组（41例）；B组：单一ATDs治疗组（76例）。基线、3个月时，TRAb-N在A组与B组两组间比较均有统计学差异（P〈0.01）。其他各组之间没有统计学差异。治疗30个月，TRAb-C在A组与B组两组间比较均没有统计学差异（P〉0.05）。结论TSAb、TSBAb的检测对于确定TRAb的功能，预测甲状腺功能变化是有意义的。ATDs治疗Graves病程中，暂时、早期小剂量应用LT4未明显影响TSAb和TSBAb。 ObjectiveChanges of thyroid stimulating antibody（TSAb） and thyroid stimulating blocking antibody（TSBAb） in the treatment of anti-thyroid drugs（ATDs）, and the effect of ATDs combining with levothyrocine（LT4） on TSAb and TSBAb were analyzed.MethodsUsing recombinant Trxfus. TSHRn protein and Trxfus. TSHRc protein as antigens, and TSH receptor antibody（TRAb）-N（TSAb binding hot spots）, TRAb-C（TSBAb binding hot spots）in the serum of thyroid disease patients were measured with ELISA. The changes of TRAb-N, TRAb-C over 36 months in 117 TRAb-N positive Graves′ patients with hyperthyroidism were analyzed retrospectively. In the course of treatment, 41 cases as A group with ATDs and LT4 treatment, 76 cases as B group with only ATDs, The changes of TRAb-N and TRAb-C were observed in the two groups.Results（1）According to the change of TRAb-N, 117 TRAb-N positive Graves′ patients with hyperthyroidism were different. In group Ⅰ, 10 patients continued to have persistently positive TSAb and continued to have hyperthyroidism, remission rate 0%. In group Ⅱ, 17 patients showed complicated TRAb-N changes, 12 of 17 patients got relapse, 5 of 17 patients got remission, remission rate 29.4%. And in group Ⅲ, with TRAb-N dropping gradually, 15 of 89 patients got relapse, 74 of the 89 patients got remission, remission rate 83.1%. Three groups were significantly different with χ2 test（P〈0.01）. One of the 117 TRAb-N positive Graves′ patients with hyperthyroidism developed TRAb-C positive hypothyroidism. （2）According to combining with and without LT4 during the treatment of ATDs, the patients were divided into 2 groups（Group A： ATDs combined with LT4; Group B： only ATDs）. These 2 groups were significantly different in TRAb-N at baseline and 3 months（P〈0.01）, TRAb-C between two groups were not significantly different in all times（P〉0.05）.ConclusionTSAb and TSBAb can be used to document TRAb-function, which is significant for us to predict the changes of thyroid function

关 键 词： 抗甲状腺药物 左甲状腺素 甲状腺刺激性抗体 甲状腺刺激阻断性抗体